CureVac N.V. Reports Q1 2025 Financial Results Amid Strategic Restructuring

Curevac N.V. ( (CVAC) ) has released its Q1 earnings. Here is a breakdown of the information Curevac N.V. presented to its investors.

CureVac N.V. is a global biopharmaceutical company focused on developing transformative medicines using messenger RNA (mRNA) technology, primarily targeting oncology and infectious diseases. The company recently reported its financial results for the first quarter of 2025, highlighting a significant decrease in revenue compared to the previous year, primarily due to changes in collaboration agreements and strategic restructuring. Key financial metrics showed a net loss of EUR 52,084k, with operating losses reduced to EUR 54,727k from EUR 73,317k in the previous year. The decrease in revenue was attributed to the restructuring of agreements with GlaxoSmithKline (GSK), while research and development expenses increased due to a strategic focus on mRNA opportunities. Despite financial challenges, CureVac continues to advance its pipeline, particularly in oncology, with promising developments in cancer precision immunotherapy and new vaccine candidates. Looking forward, CureVac’s management remains focused on leveraging its mRNA technology to address unmet medical needs, with ongoing efforts in strategic partnerships and clinical trials expected to drive future growth.